Biotech firm RootPath has secured $7m in venture funding to continue its research into personalised cancer cell drug therapies. The funding, which came mainly from Sequoia China, along with further contributions from Volcanics Venture, Baidu Ventures and Nest. In a blog post announcing the investment, founder Dr David Liu said that his company had been working on personalized medicine for more than 10 years RootPath's approach is similar to that used in CAR-T technology. However, whereas CAR-T targets a specific antigen on a tumor, by addressing a range of different tumour targets, RootPath's cell therapy also aims to prove effective on solid tumours.
Biotech firm RootPath has secured $7m in venture funding to continue its research into personalised cancer cell drug therapies. The funding, which came mainly from Sequoia China, along with further contributions from Volcanics Venture, Baidu Ventures and Nest.Bio Ventures, will be used to support preclinical development of the technology. RootPath's approach is similar to that used in CAR-T technology. However, whereas CAR-T targets a specific antigen on a tumor, by addressing a range of different tumour targets, RootPath's cell therapy also aims to prove effective on solid tumours.